$MIRM News

TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140

RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $135

Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Lowers Price Target to $137

HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript

Mirum Pharmaceuticals (NASDAQ:MIRM) Slides on Wider Loss and Volixibat Delay Despite Revenue Beat

CORRECTION: Mirum Pharmaceuticals Q2 Adj. EPS $(0.80) Misses $(0.68) Estimate, Sales $176.243M Beat $166.122M Estimate

Mirum Pharmaceuticals Raises FY2026 Sales Guidance from $660.000M-$680.000M to $680.000M-$700.000M vs $675.249M Est

Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $148

Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio

JP Morgan Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $125

The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug Zilurgisertib

Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?

Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?

Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $146

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $150

Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL Congress